Biopharma and biotech in Q3: Were the glimmers of light a false dawn?
What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether a year that started out looking pretty grim is actually staging a turnaround that a beleaguered industry would welcome.
Were small biotechs finally accepting the inevitable and taking deals that they’d have laughed at a year ago? And are the big pharma players starting to work on plugging the pipeline ahead of the impending patent cliff? Download your copy now to find out.